Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Shares Shorted: Short Interest Down 58.9% in October

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX – Get Free Report) was the recipient of a large decline in short interest during the month of October. As of October 30th, there was short interest totaling 27,571 shares, a decline of 58.9% from the October 15th total of 67,048 shares. Currently, 0.5% of the company’s stock are sold short. Based on an average trading volume of 189,130 shares, the days-to-cover ratio is presently 0.1 days.

Hedge Funds Weigh In On Evaxion A/S

Several institutional investors and hedge funds have recently modified their holdings of EVAX. Annis Gardner Whiting Capital Advisors LLC bought a new position in Evaxion A/S during the 1st quarter valued at about $112,000. Renaissance Technologies LLC bought a new position in shares of Evaxion A/S during the 1st quarter valued at approximately $146,000. Finally, Rathbones Group PLC bought a new stake in Evaxion A/S during the 1st quarter worth approximately $170,000. 11.04% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Evaxion A/S to a “hold” rating in a report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Evaxion A/S in a report on Tuesday, October 6th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.25.

Read Our Latest Research Report on Evaxion A/S

Evaxion A/S Price Performance

EVAX traded up $0.03 during midday trading on Monday, hitting $2.77. The stock had a trading volume of 27,117 shares, compared to its average volume of 95,133. The company has a market cap of $24.99 million, a P/E ratio of -2.29 and a beta of 0.60. The business has a fifty day moving average of $3.13 and a 200 day moving average of $3.43. Evaxion A/S has a 1 year low of $2.65 and a 1 year high of $6.92. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.06 and a current ratio of 5.06.

Evaxion A/S Company Profile

(Get Free Report)

Evaxion A/S is a Denmark-based biotechnology company that uses artificial intelligence to discover and develop immunotherapies and vaccines. Its research focuses on treatments for cancer and infectious diseases, with the goal of identifying targets that can prompt the immune system to recognize and attack disease. The company’s pipeline includes personalized cancer immunotherapy candidates, including EVX-01, as well as vaccine programs for cancer and infectious diseases. Evaxion uses proprietary AI platforms to analyze biological data and identify potential targets for these programs.

See Also

Receive News & Ratings for Evaxion A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion A/S and related companies with MarketBeat.com's FREE daily email newsletter.